Unlock instant, AI-driven research and patent intelligence for your innovation.

Nanovesicles derived from bacteria of genus sphingomonas and uses of same

A technology of sphingomonas and vesicles, which is applied in the direction of bacterial medical raw materials, cosmetic preparations, skin care preparations, etc., and can solve problems such as diagnosis and treatment that have not been reported

Pending Publication Date: 2021-04-13
MD HEALTHCARE INC
View PDF8 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of vesicles derived from bacteria of the genus Sphingomonas (including the above-mentioned bacteria) for diagnosis and treatment of incurable diseases such as cancer, cardiovascular disease, and atopic dermatitis has not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nanovesicles derived from bacteria of genus sphingomonas and uses of same
  • Nanovesicles derived from bacteria of genus sphingomonas and uses of same
  • Nanovesicles derived from bacteria of genus sphingomonas and uses of same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0102] Example 1. Analysis of in vivo absorption, distribution and excretion patterns of bacteria and bacteria-derived vesicles

[0103] To assess whether bacteria and vesicles derived from bacteria are absorbed systemically through the gastrointestinal tract, the following experiments were performed. First, a dose of 50 μg each of fluorescently labeled bacteria and bacteria-derived vesicles was orally administered to the stomach of mice, and fluorescence was measured after 0 min, 5 min, 3 h, 6 h and 12 h. Observe the whole image of the mouse as Figure 1A As shown, the results showed that the bacteria were not absorbed systemically, but the vesicles derived from the bacteria were absorbed systemically at 5 minutes after administration, and obvious fluorescence was observed in the bladder 3 hours after administration, so it can be seen that the vesicles is excreted into the urethra. Furthermore, it can be seen that vesicles are present in vivo until 12 hours after administrat...

Embodiment 2

[0105] Example 2. Evaluation of Bacteria and Bacteria-Derived Vesicles Penetrating the Protective Membrane of the Intestinal Mucosa

[0106] To assess whether bacteria and bacteria-derived vesicles cross the protective mucosal membrane to infiltrate tissues, after direct administration of bacteria and bacteria-derived vesicles to the intestine, the ability to pass through the protective mucosal membrane was evaluated by immunohistochemistry. Permeability of intestinal tissue. To assess the presence of bacteria and vesicles in mucosal tissues, antibodies against bacteria and vesicles were prepared, attached to green fluorescent protein (GFP) and used, and in combination with 4,6-diamidino 2-phenyl After indole (DAPI) staining, it was observed under a microscope.

[0107] As a result, it was demonstrated that bacteria failed to pass through the protective membrane of the mucosa, whereas vesicles derived from bacteria passed through the mucosa and penetrated into the intestinal ...

Embodiment 3

[0108] Example 3. Metagenomic Analysis of Bacterial-Derived Vesicles in Clinical Samples

[0109] Blood or urine was first placed in a 10 ml tube and the suspension was pelleted by centrifugation (3,500 xg, 10 min, 4°C), then only the supernatant was transferred to a new 10 ml tube. After removing bacteria and impurities using a 0.22-μm filter, transfer them to a Centriprep tube (50kD centrifugal filter) and centrifuge at 1,500×g and 4°C for 15 minutes, discard the material smaller than 50kD, and the residue Concentrate to 10ml. After bacteria and impurities were removed again using a 0.22-μm filter, ultracentrifugation was performed at 150,000 × g and 4 °C for 3 h using a 90Ti type rotor, the supernatant was discarded, and the aggregated precipitate was dissolved in saline ( PBS).

[0110] Internal DNA was extracted from lipids by boiling 100 μl of vesicles isolated by the method described above at 100 °C, followed by cooling on ice for 5 min. Then, in order to remove the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The present invention relates to vesicles derived from bacteria of the genus Sphingomonas, and uses of same. The present inventors confirmed through experiments that compared to a normal individual, there is a significant decrease of said vesicles in clinical samples of patients with cirrhosis, liver cancer, myocardial infarction, kidney failure, diabetes, brain tumor, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, and that an administration of vesicles isolated from the strains significantly suppresses the secretion of inflammatory mediators by pathogenic vesicles, such as vesicles derived from E. coli, wherein said vesicles, when orally administered, are distributed to brain tissues. Accordingly, the vesicles derived from bacteria of the genus Sphingomonas according to the present invention have promising uses in: developing detection methods for cirrhosis, liver cancer, myocardial infarction, kidney failure, diabetes, brain tumor, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis; compositions for preventing, alleviating or treating said diseases; and drug carriers enabling the delivery of drugs to the brain.

Description

technical field [0001] The present invention relates to nanovesicles derived from bacteria of the genus Sphingomonas and uses thereof, and more particularly, to the use of nanovesicles derived from bacteria of the genus Sphingomonas to diagnose liver cirrhosis, liver cancer, and myocardial infarction , renal insufficiency, diabetes, brain tumor, mild cognitive impairment, dementia, depression, autism and atopic dermatitis, etc., comprising the combination of the vesicles for preventing, alleviating or treating the diseases A substance, a composition comprising the vesicle for delivering a drug for treating brain diseases, and the like. [0002] This application claims the priority and benefit of Korean Patent Application Nos. KR10-2018-0158623 and KR10-2019-0132138 filed with the Korean Intellectual Property Office on December 10, 2018 and October 23, 2019, respectively, and these All content disclosed in the specification and drawings of the application is incorporated into ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/689A23L33/135A61K35/74A61P35/00A61P9/10A61P1/16A61P13/12A61P3/10A61P25/28A61P25/24A61P25/00A61P17/00A61K8/99A61Q19/00
CPCA23L33/135A61K35/74A61P1/16A61P3/10A61P13/12A61P17/00A61P35/00C12Q1/689C12Q1/6886C12Q1/6883A61K8/99A61Q19/00A23V2002/00A61P29/00C12Q1/6806
Inventor 金润根
Owner MD HEALTHCARE INC